Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit www.biocytogen.com
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Ultivue’s InSituPlex® technology eliminates the need for assay development and enables scientists to unmask and analyze the true biological context of tissue samples. UltiMapper™ kits are fully optimized mIHC panels that provide uninhibited co-localization of multiple markers for deep single-cell phenotyping.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
GemPharmatech is a global company providing high-quality products and model systems for discovery, testing, development and production of new drugs and therapeutic solutions. GemPharmatech is one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners across the world. With advance gene editing technology, GemPharmatech has created and produced a large collection of over 14,000 transgenic mouse models for therapeutic applications.
As a leading recombinant protein and antibody manufacturer, Sino Biological has the largest validated recombinant protein bank (6000+) in the world covering existing drug targets, cytokines, and viral proteins. The reagents also include immune checkpoint and CAR-T cell targets supporting immuno-oncology research.
Based on its rich experience and expertise, Sino Biological also provides customized services for recombinant production of proteins and antibodies, as well as for traditional antibody development, to global biotech and biopharma customers.
Quanterix™ Corporation is digitizing biomarker analysis with the goal of advancing the science of precision healthcare. Our ultra-sensitive technology platform, Simoa®, enables researchers to quantify a range of disease biomarkers at lower levels than ever before, in most common sample types. Simoa’s ultra-sensitivity, multiplex detection capability and flexibility in custom assay development are advancing both academic research and drug development both in our customers' own facilities and by contract in our CLIA-certified Quanterix Accelerator Laboratory.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.
PHC Holdings Corporation is a global healthcare company with its products and services used in more than 125 countries. Subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia and LSI Medience Corporation. The company develops, manufactures, sells and services medical equipment and solutions across the diabetes management, diagnostics, life sciences and healthcare services. Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. URL: www.phchd.com
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
“ CELLINK began as the first bioink company in the world. Today, we’re the global leader for designing and commercializing bioprinting technologies. Our innovations enable researchers to 3D print organs and tissue for applications that span industries, from pharmaceutical to cosmetic. From bioinks to bioprinting and cell dispensing to live cell imaging, we’re committed to supporting our collaborators with state-of-the-art capabilities to change the future of medicine. To read more about CELLINK, visit www.cellink.com.”
evorion biotechnologies offers custom development services and access to a unique, proprietary functional phenomics pipeline for in-depth multi-parametric analysis of thousands of cell-cell interactions at single-cell resolution. For the first time, researchers can connect a single cell’s functional phenotype with multi-omics data, opening up a new realm of novel insights into cancer-immune cell interactions that will revolutionize cell therapies. Let us partner in advancing human medicine by developing the next generation of adoptive cell therapies.
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno oncology.
Our proprietary AI target discovery engine is called “Diamond.”
Diamond is AI big data science meeting target identification, dramatically compressing man years and billions of drug development dollars to develop a live drug.
Our first product is Alexis-Pro and Alexis-ISO, off-the-shelf allogenic chPD1, and iso-mesothelin CAR-T(s) for solid tumor.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
For its Biopharma partners, HalioDx has developed the Immunogram, a clinical research platform allowing multimodal analysis to understand the tumor microenvironment. It integrates Immunoscore® assays, innovative technologies like Multiplex Spatial Tissue Analysis (Brightplex®) and molecular testing (NGS, Immunosign® Gene Expression Signatures).
IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.
.png)
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Altis Biosystems has developed a series of in vitro human intestinal cell models called Repligut® Systems which are developed from the different intestine regions and can be used for compound screening, disease modelling, toxicity, efficacy, host-pathogen interactions and basic research studies. We are proud to have industry-leading scientists on our team who share a passion for creating high-throughput, scalable, and translatable products and services to support research to improve gut health.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.
